CoChat

Selective progesterone receptor modulators

Whitaker, Lucy H.R., Williams, Alistair R.W., Critchley, Hilary O.D. · 2014 · Current Opinion in Obstetrics & Gynecology
Cited by 35

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

PURPOSE OF REVIEW: Review of recent data from clinical trials and descriptions of endometrial morphology with administration of selective progesterone receptor modulators (SPRMs). RECENT FINDINGS: Recent reports concerning administration of SPRMs, specifically the efficacy of ulipristal acetate in reducing fibroid size and rapid control of menstrual blood loss, have renewed clinical interest in this class of compound. Histological data from studies with SPRMs report that this class of drugs is associated with progesterone receptor modulator-associated endometrial changes. Data on mechanisms of action are lacking. The antagonistic progesterone effect of SPRMs has shown promising results in animal studies with endometriosis. Sex steroid receptor effects of PRMs outside the reproductive tract raise the potential for use in neurology and oncology, and although there are several randomized trials in these areas, there are limited small studies published to date. SUMMARY: The SPRM ulipristal acetate is an effective treatment for preoperative treatment of fibroids and a reliable emergency contraceptive. This class of compounds holds the potential for long-term effective medical management of fibroids and may have utility in the management of other sex steroid-dependent conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/gco.0000000000000082

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 39

  1. Mutter, 2008, The spectrum of endometrial pathology induced by progesterone receptor modulators., Mod Pathol, 21, 591, 10.1038/modpathol.2008.19 · DOI · Paper page
  2. Williams, 2007, The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata., Hum Reprod, 22, 1696, 10.1093/humrep/dem026 · DOI · Paper page
  3. Engman, 2009, Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial., Hum Reprod, 24, 1870, 10.1093/humrep/dep100 · DOI · Paper page
  4. Wilkens, 2009, Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene., PTEN Hum Reprod, 24, 1036, 10.1093/humrep/den494 · DOI
  5. Williams, 2012, Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate., Int J Gynecol Pathol, 31, 556, 10.1097/PGP.0b013e318251035b · DOI · Paper page
  6. Donnez, 2014, Long-term treatment of uterine fibroids with ulipristal acetate., Fertil Steril, 101, 1565, 10.1016/j.fertnstert.2014.02.008 · DOI · Paper page
  7. Maruo, 2000, Effects of progesterone on uterine leiomyoma growth and apoptosis., Steroids, 65, 585, 10.1016/S0039-128X(00)00171-9 · DOI
  8. Talaulikar, 2012, Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids., Eur J Obstet Gynecol Reprod Biol, 165, 135, 10.1016/j.ejogrb.2012.07.023 · doi:10.1016/j.ejogrb.2012.07.023
  9. Donnez, 2012, Ulipristal acetate versus placebo for fibroid treatment before surgery., N Engl J Med, 366, 409, 10.1056/NEJMoa1103182 · DOI · Paper page
  10. Donnez, 2012, Ulipristal acetate versus leuprolide acetate for uterine fibroids., N Engl J Med, 366, 421, 10.1056/NEJMoa1103180 · DOI · Paper page
  11. Chabbert-Buffet, 2012, The immninent dawn of SPRMs in obstetrics and gynecology., Mol Cell Endocrinol, 358, 232, 10.1016/j.mce.2012.02.021 · DOI
  12. Tristan, 2012, Mifepristone for uterine fibroids., Cochrane Database Syst Rev, 8, CD007687
  13. Shen, 2013, Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis., Fertil Steril, 100, 1722, 10.1016/j.fertnstert.2013.08.039 · DOI
  14. Wilkens, 2008, Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy., J Clin Endocrinol Metab, 93, 4664, 10.1210/jc.2008-1104 · DOI · Paper page
  15. Horak, 2012, Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo., Int J Endocrinol, 2012, 436174, 10.1155/2012/436174 · DOI
  16. Creinin, 2006, Progesterone receptor modulator for emergency contraception: a randomized controlled trial., Obstet Gynecol, 108, 1089, 10.1097/01.AOG.0000239440.02284.45 · DOI · Paper page
  17. Brache, 2013, Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens., Contraception, 88, 611, 10.1016/j.contraception.2013.05.010 · DOI
  18. Brache, 2012, Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women., Contraception, 85, 480, 10.1016/j.contraception.2011.10.003 · DOI
  19. Brown, 2002, Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5mg per day for 120 days., J Clin Endocrinol Metab, 87, 63, 10.1210/jcem.87.1.8140 · DOI
  20. Lakha, 2007, A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)., Hum Reprod, 22, 2428, 10.1093/humrep/dem177 · DOI
  21. Stoeckemann, 1995, Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats., Hum Reprod, 10, 3264, 10.1093/oxfordjournals.humrep.a135900 · DOI · Paper page
  22. Li, 2012, Effect of mifepristone on COX-2 both in eutopic and ectopic endometrium in mouse endometriotic model., Arch Gynecol Obstet, 286, 939, 10.1007/s00404-012-2379-2 · DOI
  23. Cohan, 2014, Pasireotide and mifepristone: new options in the medical management of Cushings disease., Endocr Pract, 20, 84, 10.4158/EP13127.RA · DOI
  24. Debono, 2013, Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study., PLoS One, 8, e60984, 10.1371/journal.pone.0060984 · DOI · Paper page
  25. Schairer, 2000, Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk., J Am Med Assoc, 283, 485, 10.1001/jama.283.4.485 · DOI · Paper page
  26. Klijn, 2000, Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer., Steroids, 65, 825, 10.1016/S0039-128X(00)00195-1 · DOI
  27. Poole, 2006, Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist., Science, 314, 1467, 10.1126/science.1130471 · DOI · Paper page
  28. Robertson, 1999, Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer., Eur J Cancer, 35, 214, 10.1016/S0959-8049(98)00388-8 · DOI
  29. Communal, 2012, Ulipristal acetate does not impact human normal breast tissue., Hum Reprod, 27, 2785, 10.1093/humrep/des221 · DOI
  30. Moe, 2009, High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis., Anticancer Res, 29, 1053
  31. Jurado, 2009, Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study., Oncol Rep, 22, 1237
  32. El Etreby, 2000, Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice., Prostate, 42, 99, 10.1002/(SICI)1097-0045(20000201)42:2<99::AID-PROS3>3.0.CO;2-I · doi:10.1002/(sici)1097-0045(20000201)42:2<99::aid-pros3>3.0.co;2-i
  33. Tieszen, 2011, Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and nonreproductive origin regardless of progesterone receptor expression., BMC Cancer, 11, 207, 10.1186/1471-2407-11-207 · DOI
  34. Goyeneche, 2007, Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo., Clin Cancer Res, 13, 3370, 10.1158/1078-0432.CCR-07-0164 · doi:10.1158/1078-0432.ccr-07-0164
  35. Goyeneche, 2012, Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2., Invest New Drugs, 30, 967, 10.1007/s10637-011-9655-z · DOI
  36. Hernandez-Hernandez, 2012, Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines., J Steroid Biochem Mol Biol, 132, 127, 10.1016/j.jsbmb.2012.04.005 · DOI
  37. Ramaswamy, 2012, Study of effectiveness of mifepristone for glioma cell line growth suppression., Br J Neurosurg, 26, 336, 10.3109/02688697.2011.629696 · DOI
  38. Gamarra-Luques, 2012, Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy., BMC Cancer, 12, 200, 10.1186/1471-2407-12-200 · DOI
  39. Li, 2013, Mifepristone sensitizing cisplatin for cervical adenocarcinoma HeLa cell sensitivity to chemotherapy and its mechanism., Eur J Gynaecol Oncol, 34, 142

Cited by

See all 35

Metadata

Authors
Whitaker, L. H. R., Williams, A. R. W., & Critchley, H. O. D.
Venue
Current Opinion in Obstetrics & Gynecology
Published
2014-08
Volume
26
Issue
4
Pages
237-242
ISSN
1040-872X (ISSN-L)
OpenAlex
W1988595534
Cited by
35
References
5
FWCI
2.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective progesterone receptor modulators. https://app.cochat.ai/papers/10.1097/gco.0000000000000082
The paper
Whitaker, L. H. R., Williams, A. R. W., & Critchley, H. O. D. (2014). Selective progesterone receptor modulators. Current Opinion in Obstetrics & Gynecology. https://doi.org/10.1097/gco.0000000000000082

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.